What happened
Marrow Therapeutics, a Watertown, Massachusetts startup, revealed its technology on Tuesday along with a $120 million Series B financing with OrbiMed as lead investor, lifting its total funding to $173 million, MedCity News reported. The company spent close to three years developing its approach out of public view and is now advancing its lead program, MAR-101, for sickle cell disease and beta thalassemia.
CEO Romesh Subramanian said the company's drugs attach to transferrin receptors, which bone marrow cells carry in large numbers to take in iron, so the medicine is carried inside without disrupting iron uptake. MAR-101 links a receptor-targeting antibody to a small interfering RNA meant to lower BCL11a, a protein involved in blood cell development. He said monkey data showed reduced BCL11a and fetal hemoglobin induction.
Marrow is formulating MAR-101 as an under-the-skin injection that patients could give themselves at home and that would stay stable at room temperature. The candidate is in late preclinical work that could support a request to the FDA to begin human trials. Subramanian did not give a timeline and indicated the company is open to working with pharmaceutical partners.
Context
Marrow was created and incubated by Scion Life Sciences in 2024, and a $53 million Series A with Scion and venBio as co-leads followed the next year, kept quiet while the company secured its intellectual property. Transferrin receptor delivery has precedent: Denali Therapeutics' Avlayah won FDA approval for Hunter syndrome in March, and Dyne Therapeutics, which Subramanian previously led, uses the receptor to reach muscle.
ブリーフィング
1週間のテックニュースを1通のメールで。
読む価値のある記事を毎週お届けします。配信停止はいつでも可能です。
